Joseph Baroldi, Chief Business Officer at Ionis Pharmaceuticals (NASDAQ: IONS), purchased 5,619 shares on April 16, 2026. U.S. Securities and Exchange Commission (SEC) filings reveal the transaction averaged $74.56 per share, totaling $418,952.
Purchase Details and Stock Context
The shares traded between $74.12 and $75.01 during the buy. IONS currently trades at $75.71, reflecting a 167% rise over the past year. Analysis indicates the recent purchase occurred at a significant discount to current valuations, with earnings scheduled for April 29.
Baroldi also vested 10,837 restricted stock units (RSUs) at $0.00 per share, resulting in zero value. This fulfills obligations under a 2011 incentive plan framework, including performance-based RSUs and ongoing totals.
Subsequent Sales and Insider Activity
Following the purchase, Baroldi directly sold 46,535 IONS shares. He indirectly disposed of 4,347 shares through his spouse. These mark among the largest recent insider transactions at Ionis Pharmaceuticals.
Analyst Optimism Drives Momentum
Barclays recently raised its price target on Ionis from $95 to $106, maintaining an Overweight rating. The upgrade stems from Tryngolza sales projections reaching $40,000.
RBC Capital reaffirmed Outperform with a $95 target, citing robust obesity trial data and anticipated growth in cardiovascular and cardiometabolic segments. Raymond James initiated coverage with Outperform and a $104 target, highlighting promising sHTG results.
H.C. Wainwright adjusted its Buy rating to a $120 target post-Tryngolza Phase 3 obesity data. William Blair reaffirmed Outperform, noting Tryngolza’s peak sales potential despite early commercialization, while emphasizing competitive positioning.
These updates reflect positive price action and momentum from Ionis Pharmaceuticals’ developments, boosting investor confidence in its pipeline.
